Search En menu en ClientConnect
Top 5 search results See all results Advanced search
Top searches
Most visited pages
    Reference: 20200708
    Release date: 21 March 2022

    Promoter – Financial Intermediary

    UCB SA



    The project concerns investments in research and development (R&D) activities and in the construction of an advanced manufacturing plant that will be located in existing promoter facilities in Belgium.


    The project aims at improving the health of European citizens, increasing the competitiveness and boosting the innovative capacity of European health-related industries and businesses. The project focuses on neuroscience and immunology in particular neuro-degeneration, neuro-inflammation and rare diseases as well as autoimmune diseases, which are mostly still underserved and leave a high clinical unmet need.


    Proposed EIB finance (Approximate amount)

    EUR 350 million

    Total cost (Approximate amount)

    EUR 975 million

    Environmental aspects

    The project includes the construction of a new plant to manufacture pharmaceutical products. This activity is listed in the Annex II of the Environmental Impact Assessment (EIA) Directive. Whether a EIA under the directive 2014/52/EU is required and other environmental details will be verified during the project appraisal.


    The Promoter is a private company not operating in the Utilities sector and not having a status of a contracting entity. Thus it is not covered by EU Directives on procurement.


    Signed - 18/11/2021


    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Related tags

    Belgium Industry